

g aggaggct**Ag** cgggaaagtg gtgcaggata taatgccgtg cctgcatttc
 gtgaagggggg aggagaagga gccgtcgaag gag**AgcAgc**gc gcggcacgaa gaagctgagc
 gaggaggtga agacgacgga gcagaagagg gaggcctgca agtgcatagt gcgcgccacg
 aagggcatct ccggtatcaa aaatgaactt gtcgccgagg tccccaagaa gtgcgatatt
 aagaccactc tcccgcccat caccgccgac ttcgactgct ccaagatcca aagtactatt
 ttcagagggtt actat

GGATTC

caag aaacc**Agcgg** gactatggtg agagcgctga tgccgtgcct gccgttcgtg
 caggggaaag agaaagagcc gtcaaagggg **AgcAgc**cagcg gcgccaaaag attggacggg
 gagacgaaga cggggccgca gaggggtgcac gcttgtgagt gcatccagac cgccatgaag
 acttattccg acatcgacgg gaaactcgtc agcgaggtcc ccaagcactg cggcatcggt
 gacagcaagc tcccgcccat tgacgtcaac atggactgca agacagttgg agtggttcct
 cggcaacccc aacttccagt ctctctccgt catggtcccg tcacggggcc aagtgatccc
 gccacaaaag cacggttgga gagaccccag attagagtgc cgccccccgc accggaaaaa
 gcc TAA

Fig. 1

2/9

1 50
EEASGKVVQD IMPCLHFVKG EEKEPSKESS SGTKKLSEEV KTTEQKREAC

51 100
KCIVRATKGI SGIKNELVAE VPKKCDIKTT LPPITADFDC SKIQSTIFRG

101 150
YYGFQETSGT MVRALMPCLP FVQGKEKEPS KGSSSGAKRL DGETKKTGPQR

151 200
VHACECIQTA MKTYSIDIDGK LVSEVPKHCG IVDSKLPPID VNMDCKTVGV

201 243
VPRQPQLPVS LRHGPVTGPS DPAHKARLER PQIRVPPPAP EKA

Fig.2

3/9




FIG. 3

4/9




Fig 4

Binding inhibition
ELISA

	Dimer W.T	PjEDcys
Patient 1	68%	7%
Patient 2	56%	3,5%
Patient 3	62%	10%
Patient 4	62%	8%
Patient 5	62%	8%

Fig. 5

6/9




Fig. 6

7/9




Fig 7

8/9

**% of human IgE
binding inhibition**

<i>P. judaica</i> extract	Expj	rParj1	rParj2	rParj1 rParj2
Patient 1	94	10	80	80
Patient 2	93	53	74	74
Patient 3	90	35	37	80
Patient 4	98	59	85	86
Patient 5	100	57	29	67
Patient 6	91	29	65	69
Patient 7	94	38	58	79
Average	94,3	40,1	61,1	76,5

Fig. 8

9/9

**% of human IgE
binding inhibition**

tested Protein	% of inhibition
rParj 1	95%
PjA	16%
PjB	85%
PjC	14%
PjD	15%

Fig. 9